A Functional Magnetic Resonance Imaging Study to Investigate ATP-sensitive Cough Neural Pathways in Patients With Chronic Cough Hypersensitivity
Phase: NA
Conditions: Cough
Sponsor: Stuart Mazzone

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 1 
 
 
Study Title:  
 
A functional magnetic resonance imaging study to investigate ATP-sensitive 
cough neural pathways in patients with chronic cough hypersensitivity. 
 
Clinicaltrials.gov registration number: 
NCT03722849 
 
Institution Name:  
The University of Melbourne 
 
PI contact details: 
A/Prof Stuart Mazzone 
Department of Anatomy and Neuroscience 
The University of Melbourne 
Parkville, VIC 3010 
AUSTRALIA 
+61(0)383446457 
stuart.mazzone@unimelb.edu.au 
 
 

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 2 
 
Objectives & Hypotheses  
To identify the neural circuits involved in ATP-dependent cough sensitization in humans by 
determining whether ATP-sensitive pathways in the brainstem and brain are altered in 
patients with chronic cough. 
 
Clinical hypothesis.  
ATP contributes to the development of cough hypersensitivity in patients by enhancing the 
neural activations mediated by vagal pathways involving jugular ganglia sensory neurons.   
 
BACKGROUND TO PROBLEM 
 
Chronic cough is one of the commonest clinical problems encountered by doctors both in 
general and hospital practice (1), that can persist for months and years. It remains a difficult 
problem to manage because of our poor understanding of the mechanisms underlying its 
initiation and persistence and the current lack of effective antitussive therapies  (2). People 
living with chronic cough report that chronic cough impacted considerably on their daily-life 
activities with a significant deterioration in health-related quality of life, leading to feeling 
fed-up and depressed (3) Chronic cough is also a very common co-morbid problem 
accompanying many pulmonary (e.g. asthma, chronic obstructive pulmonary disease 
(COPD), bronchiectasis, idiopathic pulmonary fibrosis) and non-pulmonary (e.g. gastro-
esophageal reflux disease, cardiac failure) conditions; in some patients, it exists as a distinct 
clinical entity termed ‘refractory’ or ‘idiopathic’ cough.  
 
Patients with a chronic cough report that changes in ambient temperature, laughing, talking 
on the phone for more than a few minutes, aerosol sprays, or smoky atmospheres 
characteristically trigger bouts of coughing (4, 5). In a demographic profile of chronic cough 
in 4,500 patients attending UK specialist cough clinics (and over 10,000 patients worldwide) 
(6),we found a state of hypersensitivity as a key common pathophysiological characteristic 
(7).  This has led to the Cough Hypersensitivity Syndrome (CHS)  hypothesis as an underlying 
cause of chronic cough whereby nerves (in the airway and/ or the brain) become sensitized, 

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 3 
 
activated and perhaps damaged (neuropathic cough) by irritant factors including viral 
infection, chemicals and inflammation (8). 
 
Sensory inputs from the upper and lower airways to the brainstem are relayed to higher 
brain regions where they are integrated in subcortical nuclei and then mapped to the 
cingulate, insula, orbito-frontal and somatosensory cortices in the cerebrum (9).  Studies 
using fMRI of the human brain during challenges with inhaled airway irritants have shown 
these areas to be important for the different sensory and motor responses that accompany 
coughing. Importantly, these central neural pathways function differently in chronic cough 
patients (10). Thus, responses to sensory inputs are exaggerated while those needed to 
suppress (control) coughing are depressed.  This exciting discovery has shed an entirely new 
perspective on problematic cough, suggesting that pulmonary conditions that lead to 
coughing may do so by changing the way in which the central nervous system responds to 
sensory inputs.  The striking parallels regarding peripheral and central sensitization which 
link cough and pain syndromes have prompted recent collective effort to more completely 
understand the processes leading to these neural dysfunction (11). 
 
Despite this important understanding of the process of CHS, the most important unmet 
need relates to the lack of effective antitussives. Clinically, amitriptyline and gabapentin are 
used as cough suppressants with central effects potentially on CHS pathways that remains 
to be determined, but their effect is not uniform in all patients with chronic cough (12). 
However, more recently, a blocker of the ATP receptor, P2X3, Gefapixant (600 mg twice a 
day for 14 days), has been shown to be extremely effective in suppressing the chronic cough 
of patients with an idiopathic cough, with a reduction in cough frequency by 75% when 
compared to placebo with daytime cough frequency reduced from a mean 37 coughs per 
hour to 11 coughs per hour (13). These results were confirmed in another randomized, 
double-blind, placebo-controlled, Phase 2b crossover study using lower doses of Gefapixant 
(50 mg, 100 mg, 150 mg and 200 mg twice daily for four days) demonstrated significant 
reduction in cough frequency, including at the lowest dose of 50 mg twice daily (14). 
However, contrasting with this positive effect of Gefapixant, studies using TRP receptor 
blockers such as TRPV1 and TRPA1 antagonists have failed to show any efficacy in chronic 

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 4 
 
cough patients (15-17).   Therefore, the singular potent effect of Gefapixant as an antagonist 
of P2X3 ATP receptor in suppressing cough opens a new focus of investigation in the role of 
ATP and its receptor P2X3 in CHS.   
 
RATIONALE 
 
Given that a blocker of the ATP receptor, P2X3, has been successful in inhibiting chronic 
cough, we wish to use this observation to understand the putative role of ATP sensitive 
vagal sensory neural pathways in the cough hypersensitivity syndrome. Vagal sensory 
neurons are located in the nodose and jugular vagal ganglia (Fig 1).  Nodose neurons 
developmentally originate from cells within the embryological placodes (18).  There are a 
series of placodes that form above the pharyngeal cleft during development, collectively 
referred to as the epibranchial placodes, and these comprise the geniculate, petrosal, and 
nodose placodes that eventually form the geniculate, petrosal and nodose ganglia, 
associated with the 7th, 9th and 10th cranial nerves.  By contrast, most peripheral neurons, 
including the sensory neurons of the jugular and spinal dorsal root ganglia (DRG), are 
developmentally derived from neural crest cells (18).  Jugular ganglia neurons contribute to 
the innervation of tissues of the head and neck and are phenotypically similar to DRG 
neurons, but quite distinct to nodose neurons. Because of these developmental differences, 
nodose and jugular afferent nerves have distinct activation profiles, central (brain) 
connectivity and likely serve distinct sensory functions (reviewed in (19)).  Preclinical animal 
studies, for example, suggest that only nodose neurons are responsive to ATP even though 
P2X3 receptor subunits are ubiquitously expressed in neurons of both vagal ganglia.  This is 
because only nodose neurons express P2X2 subunits needed for functional heteromeric 
channel assembly.  Intriguingly, other stimuli of nodose neurons (such as serotonin and 
adenosine) do not produce much coughing. Thus, whilst stimuli (such as capsaicin) that 
activate both jugular and nodose vagal chemically sensitive afferents evoke cough in 
conscious animals and humans, nodose chemically sensitive afferent-selective stimuli 
(including ATP) do not reliably evoke cough, and some nodose stimuli may inhibit cough in 
certain circumstances (20-22).   Indeed, there is a paucity of evidence that would support a 
role for most subtypes of nodose neurons in cough production.  This, therefore, creates a 

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 5 
 
conundrum – nodose neurons don’t evoke cough when activated but are responsive to ATP 
while jugular neurons readily evoke coughing but don’t respond to ATP ordinarily.   
However, it is important to note that this work has only been conducted on neurons from 
healthy animals, and as such how ATP dependent responses at the neuronal level changes in 
pulmonary disease is not entirely clear.   
 
Consequently, the role of nodose versus jugular afferent pathways in human chronic 
cough dependent upon purinergic mechanisms remains unclear. 
 
 
The differential organization of nodose and jugular neurons within the central nervous 
system may allow insights into the relative contribution of nodose and jugular afferent 
pathways in ATP-dependent cough in health and disease.  Thus, axonal guidance cues under 
the regulation of placodal transcription factor Phox2b attract nodose terminals to the 
medullary regions of the nucleus of the solitary tract (nTS) (23).  By contrast, the Mazzone 
group have recently shown that the neural crest derived jugular ganglia neurons have their 
central terminations in the trigeminal nuclear complex, in a little-known region called the 
paratrigeminal nucleus (Pa5) (24, 25).  Thus, in rats 
and guinea pigs injection of a retrograde tracing dye 
into the nTS labels only neurons in the nodose 
ganglia, while a comparable injection in the Pa5 
labels only jugular neurons.  Because of this 
differential brainstem wiring, the ascending 
pathways in receipt of nodose and jugular afferent 
inputs are also different (24).  Until now, this has 
been impossible to study in humans.  Consequently, 
we know nothing about the neural mechanisms 
involved in ATP dependent cough in humans, nor do 
we know how these neural processes might behave 
in patients with chronic cough.    This issue is central 
to the current funding request because our team 
Fig 1. Pulmonary jugular (red) and 
nodose 
(green) 
vagal 
sensory 
pathways are anatomically and 
functionally distinct.   

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 6 
 
has optimized methods for assessing cough neural circuit activation driven by ATP in 
humans (see preliminary data) and are positioned to make major insights into these neural 
processes. 
 
SIGNIFICANCE OF SELECTED TOPIC 
 
This is an important area of research in CHS because this provides us for the first time with 
some clues as to the potential mechanisms for CHS. ATP is known to activate and sensitize 
signal transmission at sensory sites including primary afferent neurons such as airway vagal 
afferent nerves via its P2X3-containing trimers and P2X3 antagonists are active in many 
inflammatory and visceral pain models, by inhibiting inappropriate chronic signals and 
decreasing peripheral and central hypersensitivity (26). Discovering the mechanisms by 
which P2X3 contributes to CHS may not only lead to discovery of the important peripheral 
and central pathways where P2X3 is crucial, but also to other potential targets for therapy. 
This may also lead to an understanding of the role of the P2X2 component that has been 
implicated, and to understand now to dissociate the anti-tussive effects of Gefapixant from 
its hypo- or ageustic effects. Finally, our study could provide an empirical test that would 
predict whether an antitussive would have the capacity to work or represent a new 
approach to studying the efficacy of P2X3 targeting compounds, or any other anti-tussives 
being developed. Regardless of the future applications, the work represents cutting-edge 
neuroscience in the area of cough and pulmonary sensation, and this will have impact in the 
field. 
 
PRELIMINARY DATA 
 
Peripheral effects of ATP via P2X3 receptors 
ATP has been shown to be a tussive agent particularly on chronic cough patients who were 
more sensitive than non-cough subjects to inhaled ATP (27). ATP has been shown to 
augment the cough response to capsaicin in patients with asthma (28). Gefapixant at a 
single oral dose of 50 mg did not modulate capsaicin cough responses in normal volunteers 
and chronic cough subjects while inhibiting ATP-induced cough particularly in chronic cough 

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 7 
 
subjects (22). These observations would suggest that ATP has a direct effect on the sensory 
neurons that evoke coughing through the activation of P2X3 receptors (detailed above). 
 
 
The use of fMRI to provide insights into the peripheral and central sites of activation by 
ATP/P2X3 activation  
We have generated functional brain imaging (fMRI) data to suggest that the different brain 
circuits in receipt of nodose and jugular ganglia neuron inputs (as identified in animal 
studies) are conserved in humans.  When inhaled, the tussigenic compound capsaicin (from 
hot chili peppers) indiscriminately stimulates both nodose and jugular chemosensitive 
afferents and we have published that capsaicin inhalation produces brain activations in the 
primary sensory, anterior and mid-insula, cingulate, premotor, motor and orbitofrontal 
cortices (29, 30).  These regions are presumed to encode perceptual awareness of airway 
irritation, and the associated emotional, cognitive and behavioral (motor) consequences.  
For example, activity in the human primary sensory cortex (which receives jugular ganglia 
inputs in animal studies) correlates with an individual’s perception of airway irritation (their 
perceived need/ urge to cough) while activity in the insula (in receipt of nodose inputs) 
relates closely to the actual magnitude of the delivered stimulus independent of perception.  
We have now built upon these published findings by using high resolution brainstem fMRI 
during the inhalation of ATP (expected to only activate P2X2/3 expressing nodose-derived 
airway afferents) versus capsaicin (expected to activate both jugular and nodose 
chemosensitive afferents).  Our results are striking and reveal that ATP inhalation evokes an 
in increased signal level in the brainstem regions corresponding to the nTS, while capsaicin 
inhalation produces activations in both the nTS and in an area of the dorsal spinal trigeminal 
nucleus on the lateral margins of the brainstem that contains the paratrigeminal nucleus 
(Fig 2).  Indeed, our healthy participants did not cough as much to ATP compared to 
capsaicin, consistent with studies cough in animals and humans and the relatively poor 
cough-evoking properties of ATP in healthy humans (20, 21).  However, the perception of 
airway irritation was identical between ATP and capsaicin stimuli (Fig 3).  We believe that 
cough production will ultimately be dependent upon activation of the neural circuit that 
integrates in the paratrigeminal nucleus (i.e.’ the jugular afferent pathway) and therefore 

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 8 
 
we hypothesize that there is an upregulation of the capacity of ATP to act via jugular 
ganglia pathways in chronic cough patients. 
 
The fMRI studies described above provide an exciting opportunity to assess for the first time 
which primary airway afferent pathways are likely excited or sensitized by ATP and, in turn, 
what aspects of the central processing of airway sensory information is altered by ATP.  We 
have reported previously that patients with chronic cough display functional brain 
responses consistent with a state of central sensitization (10) that closely resembles the 
central sensitization accompanying chronic pain (31).   
 
We will extend upon these findings by determining whether ATP-sensitive pathways in the 
brainstem and brain are altered in patients with chronic cough, and in doing so provide 
insight into whether ATP effects vagal afferent processing through an interaction with 
nodose and/ or jugular neural pathways.  
 
Study Design 
The study will involve 25 participants with cough hypersensitivity and 25 age and sex 
matched healthy controls. All participants will provide written informed consent to 
participate in the study, which will be approved by the Melbourne Health Human Research 
Ethics Committee (Australia). Before inclusion, all participants undergo screening interviews 
to ascertain their eligibility for the study. All participants will be non-smokers with no history 
of neurological disease or any recent history (over 8 weeks) of acute respiratory infections. 
Cough hypersensitive participants will be recruited from respiratory specialist clinics and 
included if they have experienced chronic cough (coughing for over 8 weeks) and are 
considered idiopathic/ refractory coughers (to avoid the confounds of heterogeneity of 
precipitating diseases). Healthy control participants will have no history of chronic 
respiratory disease and will be individually age and sex matched to each cough 
hypersensitive participant.  
 
Participants will attend two experimental sessions.  The first is used to ascertain their 
individual sensitivities and tolerances to inhaled challenges with capsaicin and ATP 

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 9 
 
(psychophysical testing session) and the second to determine their brain responses to 
challenge stimuli (brain imaging session).  This is not an interventional study but rather a 
comparison between responses in healthy control participants versus patients with chronic 
cough syndrome.   
 
 
 
All participants will first undergo a psychophysical testing session where their level of 
sensitivity to capsaicin and ATP is measured using a method of limits approach. The 
following measures of sensitivity are determined: stimulus dose evoking 2 coughs (C2), the 
stimulus dose required for the initial detection of an urge to cough (Cu) and the maximal 
suppressive stimulus dose where a participant can resist coughing (Smax).  Patients will 
provide subjective measures of their urge-to-cough using an eleven point numerical rating 
scale (0, no urge-to-cough; 10, maximum urge-to-cough) evoked by single breath challenges 
with tussive stimuli. The capsaicin and ATP solutions are nebulized to participants via a 

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 10 
 
facemask fabricated to deliver stimuli through oral breathing (and to be compatible for 
hands free use in an MRI scanner). Doubling doses of stimuli are used throughout the study 
ranging from 0.06μM to 125μM for capsaicin and 0.45 – 232.5mM for ATP.  Once the C2 
dose is identified, participants will receive randomized challenges with doses two 
increments above and below the C2 (C2-2, C2-1, C2, C2+1 and C2+2) to accurately measure 
the stimulus response function for each individual.  Finally, in preparation for fMRI scanning, 
participants will be challenged for 24 seconds with stimuli above and below the C2 dose to 
determine challenge stimuli doses that are tolerable for brain imaging (defined as the 
Smax).  This session is used to ascertain each participant’s sensitivities and tolerances to 
inhaled stimuli and to inform the participants about the design of the subsequent fMRI 
session. 
 
In the second session, participants return for fMRI scanning.  Structural and functional MRI 
data are collected on a Siemens Magnetom Trio 3 Tesla scanner (Siemens AG, Erlangen, 
Germany) with a 32-channel head coil located at the Monash Biomedical Imaging Facility, 
Melbourne, Australia. Anatomical T1‐weighted images are acquired in the sagittal plane 
(192 slices, 0.90 mm slice thickness, 0.84 × 0.84 mm2 in‐plane resolution, echo time (TE) 
= 2.59 ms, repetition time (TR) = 1900 ms, flip angle = 9). Two functional MRI (fMRI) scans of 
491.4 seconds duration are performed using the BOLD contrast. Functional runs are 
collected using a partial field of view (FOV) with a gradient-echo echo-planar parallel 
imaging sequence (GRAPPA, PAT factor=3, reference lines=36, TR=1790ms, TE=30ms, 27 
slices, 2.5mm thickness, 1.88mm in-plane resolution, flip angle=70 degrees).  This facilitates 
a restricted focus on the brainstem necessary to define regional activations in this area (see 
Figure 2). 
 
During image acquisition, participants lay comfortably on the scanner bed with their head 
stabilised with foam padding and hearing protection. Participants are fitted with the 
facemask and apparatus used in the psychophysical testing session. Online respiratory 
monitors are fitted around their chest throughout the experiment (AD Instruments). A 
periscope mirror attached to the scanner head coil enables participants to view a projector 

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 11 
 
screen upon which visual instructional cues are presented throughout the experimental 
session. Within each functional scanning run, three stimulus blocks of capsaicin, three of 
ATP and two of saline are administered in a pseudorandom order.  Each stimulus block lasts 
24 seconds in duration, and is separated from the next by 36.8 seconds.  Visual cues are 
used to time the participant’s inhalation with the onset of stimulus delivery in order to 
standardise the respiratory cycle between participants.  At the end of each challenge block, 
participants give a numerical rating of their urge-to-cough. 
 
Study Duration 
18 months will be required to recruit and scan 25 cough patients and 25 age/ sex matched 
healthy controls, this includes 6 months for fMRI data analysis which is time consuming. 
Total study duration will be 18 months. 
 
Statistical analysis plan 
Our team has previously published in detail our methods for analyzing functional brain 
imaging data with associated physchophysical metrics, many of which have been rigorously 
optimized by our group to control for confounding respiratory noise.  We have extensive 
experience in these types of studies and all the required expertise to analyze and interpret 
brain imaging data exists within A/Prof Mazzone’s research team in Melbourne.  This 
includes investigating relationships between behavioral measures and brain responses (e.g., 
see ref 10).  Professor Chung and Dr McGarvey will contribute to the interpretation of 
clinical metrics related to cough phenotype and cough questionnaire survey results.    
 
Variables/Time Points of Interest 
Two types of data will be collected, (1) Blood Oxygen Level Dependent signal data collected 
during fMRI scans and used to determine regional brain activity, and (2) psychophysical data 
during preliminary testing sessions and during fMRI scanning.  The latter includes the 
stimulus dose evoking 2 coughs (C2), the stimulus dose required for the initial detection of 
an urge to cough (Cu) and the maximal suppressive stimulus dose where a participant can 
resist coughing (Smax).  As part of the clinical work up of the patients we will also collect 

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 12 
 
subjective patient scores of their cough severity and quality of life, using validated tools (the 
Leicester Cough Questionnaire (LCQ)) which can be also used to help interpret fMRI data.  
The primary variable of the study is the stimulus delivered (ATP versus capsaicin) compared 
between cough patients and healthy controls, assessing the differential outcomes on BOLD 
signal changes and associated psychometrics. 
 
Statistical Methods 
Statistical analysis of psychophysical parameters will be performed with SPSS 22.0. 
Independent t- tests will be used to test the effects of group on C2, Cu and Smax thresholds. 
A repeated-measures ANOVA is used to test the effects of group, dose and their interaction 
on urge-to-cough ratings in response to random stimulus challenges.  Independent t-tests 
will be used to assess group effects on capsaicin/ ATP doses and urge-to-cough ratings 
associated with the fMRI scanning. 
 
fMRI image analysis will be performed with FEAT, version 5.98. Regressors for each dose of 
capsaicin/ ATP and rating events will be included in a general linear model that also includes 
motion parameters and confound variables to take account of physiological noise. Contrasts 
for capsaicin/ ATP doses will be averaged across the three scans for each participant and 
used in the analysis of group and between-group effects. Group contrasts include high doses 
for all participants (Like-Behaviour), and activation levels will be tested for correlations with 
Cu and frequency of coughing during repeated stimulus challenges.  Higher level analyses 
will be carried out for inter-group averaging and between-group comparisons. Z 
(Gaussianised T/F) statistic images are thresholded to define clusters of contiguous voxels 
activated at a significance level of Z > 2.3. To correct for multiple comparisons, a corrected 
cluster probability threshold (based on Gaussian Random Field Theory of p < 0.05 is applied. 
Between-group contrasts are made using two different comparisons: i) during the inhalation 
of Smax for all individuals in both groups (matched urge-to-cough sensation). Activation 
levels associated with Smax doses are tested for relationships with the Cu threshold and the 
frequency of coughing during the psychophysical sessions. 
 

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 13 
 
Multiplicity 
N/A 
 
Power/Sample Size 
Sample size estimates have been made using BOLD signal changes extracted from regions of 
interest in the data set shown in Figure 2 and analyzed with fMRIpower (32). Inclusion of 25 
participants will provide at least 80% power to detect a between-group difference of 0.48 to 
0.72 standard deviation units (analogous to Cohen's d) in the regions of interest. This is 
sufficient power to resolve significant effects of disease (chronic cough) on ATP and 
capsaicin evoked brain activations in brainstem nuclei (as shown in Figure 2, data collected 
from n=24 with one additional participant excluded because of excessive head movement 
during scanning).  Males and females will be included in the study. 
 
Adverse Incident Reporting 
We do not expect that there will be any serious adverse events during the experimental 
procedures. Should a serious event occur, the experiment will be stopped immediately and 
the Institutional health and safety guidelines will be followed. We will call a trained first aid 
officer and contact our local emergency services if required. 
 
Risks 
Inhaling capsaicin causes irritation of the throat. The irritation quickly resolves after 
exhaling. Capsaicin does not harm the tissues of the throat.  Throat irritation and urge-to-
cough are integral components of the experimental protocol. Levels of these sensations will 
be assessed using psychophysical procedures whereby the individual participant's sensitivity 
to the substances dictate the doses used in the experiment, thus avoiding excessive 
discomfort.  Adverse responses to capsaicin inhalation, other than transient throat irritation, 
are unlikely. A systematic review of the literature and personal communications with 
investigators established the absence of any adverse outcomes of capsaicin inhalation 
among 4,833 participants that included healthy adults, children, and patients with 
respiratory disease (33) Our own reports involving capsaicin inhalation are similarly without 

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 14 
 
incident (e.g., refs 6, 9, 10, 29, 30).  The amount of capsaicin inhaled is very low, equivalent 
to 0.0038%. These low levels are sufficient to evoke transient feelings of airway irritation, 
but much lower than concentrations typically encountered for other uses of capsaicin such 
as medicinal topical applications (0.025-0.25%), experimental protocols involving topical 
application to produce cutaneous hyperalgesia (i.e. 5%), or as a spray in law enforcement (1-
2%). 
 
Experience with ATP is less extensive than capsaicin, but reported effects on throat irritation 
are similar for the two stimuli (34). ATP can also cause bronchoconstriction and associated 
increases in reported dyspnea in asthma patients (35). Asthmatics will not be recruited to 
this study. 
 
MRI scanning is safe providing appropriate prescreening is performed.  Participants will be 
screened by the MRI radiographer prior to scanning to exclude any risk factors (namely 
implanted or embedded metals) before going in proximity to the high magnetic field of the 
scanners. Due to the unknown risks of MRI scanning on fetal development, women who are 
pregnant, or suspect they may be pregnant, will be excluded from participating in the study.  
On rare occasions, MRI scanning identifies unknown pre-existing pathologies in participants.  
Under such circumstances A/Prof Mazzone will contact the individual and advise them to 
consult a medical practitioner to further discuss any implications of the findings. Copies of 
the Radiology report will be forwarded to the participant and to a nominated medical 
practitioner if the participant wishes. 
 
 
 

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 15 
 
References 
1. 
Chung KF, Pavord ID. Prevalence, pathogenesis, and causes of chronic cough. Lancet. 
2008;371(9621):1364-74. 
2. 
Pavord ID, Chung KF. Management of chronic cough. Lancet. 2008;371(9621):1375-84. 
3. 
Chamberlain SA, et al. The impact of chronic cough: a cross-sectional European survey. 
Lung. 2015;193(3):401-8. 
4. 
McGarvey L, et al. Are there clinical features of a sensitized cough reflex? Pulmonary 
pharmacology & therapeutics. 2009;22(2):59-64. 
5. 
Hilton E, et al. Clinical features of the urge-to-cough in patients with chronic cough. 
Respir Med. 2015;109(6):701-7. 
6. 
Morice AH, et al. A worldwide survey of chronic cough: a manifestation of enhanced 
somatosensory response. Eur Respir J. 2014;44(5):1149-55. 
7. 
Morice AH, et al. Expert opinion on the cough hypersensitivity syndrome in respiratory 
medicine. Eur Respir J. 2014;44(5):1132-48. 
8. 
Chung KF, McGarvey L, Mazzone SB. Chronic cough as a neuropathic disorder. The 
lancet Respiratory medicine. 2013;1(5):414-22. 
9. 
Mazzone SB, et al. Representation of Capsaicin-evoked Urge-to-Cough in the Human 
Brain Using Functional Magnetic Resonance Imaging. AmJ Respir Crit Care Med. 
2007;176(4):327-32. 
10. 
Ando A, …Mazzone SB, Farrell MJ. Neural correlates of cough hypersensitivity in 
humans: evidence for central sensitisation and dysfunctional inhibitory control. 
Thorax. 2016;71(4):323-9. 
11. 
O'Neill J, McMahon SB, Undem BJ. Chronic cough and pain: Janus faces in sensory 
neurobiology? Pulmonary pharmacology & therapeutics. 2013;26(5):476-85. 
12. 
Chung KF, McGarvey L, Mazzone S. Chronic cough and cough hypersensitivity 
syndrome. The lancet Respiratory Medicine. 2016;4(12):934-5. 
13. 
Abdulqawi R, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a 
randomised, double-blind, placebo-controlled phase 2 study. Lancet. 
2015;385(9974):1198-205. 

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 16 
 
14. 
Smith JA, et al. A phase 2 dose-escalation study with AF-219, a P2X3 antagonist for the 
treatment of chronic cough. Amer J Respir Crit Care Med. 2016;193:A6524. 
15. 
Khalid S, et al. Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients 
with refractory chronic cough: a double-blind randomized controlled trial. J Allergy 
Clin Immunol. 2014;134(1):56-62. 
16. 
Morice AH. TRPA1 receptors in chronic cough. Pulmonary pharmacology & 
therapeutics. 2017;47:42-4. 
17. 
Belvisi MG, et al. XEN-D0501, a Novel Transient Receptor Potential Vanilloid 1 
Antagonist, Does Not Reduce Cough in Patients with Refractory Cough. Am J Respir 
Crit Care Med. 2017;196(10):1255-63. 
18. 
Baker CV. The embryology of vagal sensory nerves. In: Undem BJW, D., editor. 
Advances in vagal afferent neurobiology. Boca Raton FL: CRC; 2005. 
19. 
Mazzone SB, Undem BJ. Vagal Afferent Innervation of the Airways in Health and 
Disease. Physiological reviews. 2016;96(3):975-1024. 
20. 
Chou YL, et al. Opposing effects of bronchopulmonary C-fiber subtypes on cough in 
guinea pigs. American Journal of Physiology Regulatory, Integrative and Comparative 
Physiology. 2017;295(5):ajpregu003132017. 
21. 
Chou YL, et al. Differential effects of airway afferent nerve subtypes on cough and 
respiration in anesthetized guinea pigs. American journal of physiology Regulatory, 
integrative and comparative physiology. 2008;295(5):R1572-84. 
22. 
Smith et al. The effect of P2X3 antagonist (AF-219) on experimentally-evoked cough in 
healthy volunteers and chronic cough patients.  Thorax. 2016;71(Suppl 3):A17. 
23. 
D'Autreaux F, et al. Homeoprotein Phox2b commands a somatic-to-visceral switch in 
cranial sensory pathways. Proc Natl Acad Sci U S A. 2011;108(50):20018-23. 
24. 
McGovern AE, ….Mazzone, SB. Distinct brainstem and forebrain circuits receiving 
tracheal sensory neuron inputs revealed using a novel conditional anterograde 
transsynaptic viral tracing system. The Journal of Neuroscience 2015;35(18):7041-55. 
25. 
Driessen AK, …Mazzone SB, McGovern AE. The Role of the Paratrigeminal Nucleus in 
Vagal Afferent Evoked Respiratory Reflexes: A Neuroanatomical and Functional Study 
in Guinea Pigs. Frontiers in Physiology. 2015;6:378. 

 
NCT03722849: Protocol Document version date: 22nd Oct 2018 
Page | 17 
 
26. 
Ford AP, Undem BJ. The therapeutic promise of ATP antagonism at P2X3 receptors in 
respiratory and urological disorders. Frontiers in cellular neuroscience. 2013;7:267. 
27. 
Fowles HE, et al. Tussive challenge with ATP and AMP: does it reveal cough 
hypersensitivity? Eur Respir J. 2017;49(2). 
28. 
Basoglu OK, et al. Contrasting effects of ATP and adenosine on capsaicin challenge in 
asthmatic patients. Pulmonary pharmacology & therapeutics. 2017;45:13-8. 
29. 
Mazzone SB, et al. Investigation of the neural control of cough and cough suppression 
in humans using functional brain imaging. The Journal of neuroscience. 
2011;31(8):2948-58. 
30. 
Farrell MJ, … Mazzone SB. Neural correlates coding stimulus level and perception of 
capsaicin-evoked urge-to-cough in humans. NeuroImage. 2012;61(4):1324-35. 
31. 
Zambreanu L, et al. A role for the brainstem in central sensitisation in humans. 
Evidence from functional magnetic resonance imaging. Pain. 2005;114(3):397-407. 
32.  Mumford JA, Nichols TE. Power calculation for group fMRI studies accounting for 
arbitrary design and temporal autocorrelation. Neuroimage. 2008;39:261-8. 
33.  Dicpinigaitis PV, Alva RV. Safety of capsaicin cough challenge testing. Chest. 2005 
Jul;128(1):196-202 
34. Basoglu OK, et al. Effects of Aerosolized Adenosine 5'-Triphosphate in Smokers and 
Patients With COPD. Chest. 2015 Aug;148(2):430-435. 
35.  Basoglu OK, et al. Effects of aerosolized adenosine 5'-triphosphate vs adenosine 5'-
monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients 
with asthma. Chest. 2005 Oct;128(4):1905-9. 

 
 
 
EXPLANATORY STATEMENT 
Project Title: 
 
Behavioural and brain haemodynamic responses to inhalation of capsaicin and adenosine tri-phosphate (ATP) 
in patients with idiopathic chronic cough. 
Chief Investigator: Prof Stuart Mazzone 
Department of Anatomy and Neuroscience 
The University of Melbourne 
 
Phone:  83446457 
email: stuart.mazzone@unimelb.edu.au 
Human Ethical Approval number: 1852642 
 
 
You are invited to take part in this study.  Please read this Explanatory Statement in full before deciding whether 
or not to participate in this research. If you would like further information regarding any aspect of this project, 
you are encouraged to contact the researchers via the phone numbers or email addresses listed above. 
 
What does the research involve?  
The aim of this study is to identify regions in the brain that respond to inhalation of stimuli that evoke coughing. 
 
You will be invited to attend two sessions if you choose to participate in this study.  Both sessions may occur on 
the same day or be up to a week apart depending on equipment access and your availability.  
 
The first session is at either the University of Melbourne on Grattan St in Parkville or Monash Biomedical 
Imaging in Blackburn Road, Clayton, depending on what is convenient for you.  In this session you will complete 
some questionnaires about your daily experience with cough, and then take single breaths of vapour containing 
chemicals that briefly irritate the airways. These chemicals are capsaicin and adenosine tri-phosphate (ATP). 
Capsaicin is the ‘hot’ ingredient of chilli peppers. ATP is a substance inside the body that plays a role in how cells 
use energy. You will place a ventilated mask over your nose and mouth for each inhalation of the chemical 
vapour. You are likely to feel a need to cough and sometimes you will cough after inhaling the vapour. The 
sensation and coughing resolve quickly in the first or second breath that you take after you exhale the vapour. 
You will be asked to give ratings of your need to cough for each inhalation and the researcher will also confirm 
with you if the sensation is disappearing with a breath of fresh air.  This information will be used to determine a 
suitable level of stimulus to be used during the second session when brain imaging occurs.  We will first check 
that the stimulus level is tolerable for you by having you breathe in and out the chemical repeatedly during 24 
seconds and adjust the stimulus level to ensure that you only feel mild irritation. The duration of these trials is 
the same as the timing of repeated inhalations used during brain scanning. These trials will show if you are able 
to resist coughing during repeated inhalation, or if a reduction of stimulus level will be required to avoid any 
coughing.  This session will take around 1 hour to complete. 
 
Your second session will involve Magnetic Resonance Imaging (MRI) scanning of your brain. These scans will 
happen at Monash Biomedical Imaging, on Blackburn road in Clayton as this is the location of the MRI machine. 
The radiographer at the scanner will interview you to make sure it is safe for you to be scanned. You will lie on 

 
 
 
 
Page 2 of 4 
your back on a moveable bed with a circular cage around your head. The ventilated mask will be placed in 
position over your nose and mouth. You will also wear hearing protection because the scanner is noisy. The bed 
will be moved until you are in the middle of the scanner tunnel. A mirror on top of the head cage will provide a 
view along the scanner tunnel, and a TV screen outside the scanner will be in your field of view. The scanning 
will take about one hour. There will be three scans that last nine minutes and two scans that last four minutes, 
with breaks in between. During the nine-minute scans you will see visual messages on the TV that tell you when 
the chemical vapour will be pumped into the mask. The chemical vapour will be turned off after 24 seconds on 
each of nine occasions during the scan.  After each period of chemical vapour, visual information on the TV will 
appear asking you to rate your need to cough.  During the four-minute scans you will constantly inhale chemical 
vapour.  
 
Why were you invited to participate in this research? 
The objective of this research is to localise the brain regions that respond to information coming from the 
airways. You have been approached to be involved because you are either a healthy person without any 
diseases involving your airways or because you have troublesome cough that is proving difficult to treat.  
 
Source of funding  
The pharmaceutical company Merck Sharp and Dohme Australia has provided funding for this research because 
they are interested in mechanisms that lead to excessive coughing in disease. 
 
Consenting to participate in the project and withdrawing from the research 
Participation in this research is voluntary. If you consent to be involved in this research, you will be asked to sign 
and return a Consent Form. By signing the Consent Form, you indicate that you: 
- understand the information; 
- give your consent to participate in the research project; 
- consent to participate in the research processes that are described; 
- consent to the use of your information as described 
You have the right to withdraw from further participation in the research at any stage.  
You will be given a copy of the Explanatory Statement and Consent Form to keep as a record. 
 
Possible benefits and risks to participants  
There will not be any direct benefits to you as a consequence of participating in this research. Information 
obtained during this research may eventually be used to develop new methods to control unwanted coughing.  
 
Inhaling capsaicin and ATP causes irritation of the throat. The irritation quickly resolves after exhaling. The 
chemicals do not harm the tissues of the throat.  The irritation is not painful. 
 
There are no known risks from the MRI scanning except for dangers associated with metal implants such as 
cardiac pacemakers, prosthetic heart valves, implanted cardiac defibrillators, and vascular clips. The scanner 
generates a very strong magnetic field, so if you have metal implants you will not be able to participate. Bringing 
metal into the scanner can be dangerous because of the very strong magnetic field. You must not bring any 
metal into the MRI scanner. Before you go into the scanner, you will be thoroughly screened by an MRI 

 
 
 
 
Page 3 of 4 
radiographer to ensure you are not at risk. There is no harmful radiation with MRI scanning and injections are 
not required.  
 
It is not known if MRI scanning is harmful to the unborn child. Therefore, females should not participate in this 
project if you know or suspect that you are pregnant.  
 
Some participants may experience minor discomfort during MRI scanning. Because the scanner operation 
generates a loud hammering noise, you will wear special earmuffs to reduce the noise level. In addition to the 
noise, some participants may find the tunnel shape of the scanner confining. In very rare cases, the experience 
may be so claustrophobic that it is not possible to continue. When you are in the scanner you have visual and 
verbal contact with the researchers and you also have a button to squeeze to stop the scanning immediately 
should you find it necessary. 
 
What happens if something abnormal is found on my scans? 
As part of your study we will obtain a limited number of pictures of your brain.  Our research studies are 
designed to improve our knowledge of the brain. They are not designed for diagnostic or clinical purposes.  
After your scan, a specialist will examine these pictures (this will not be done on the day of your study). Minor 
changes are sometimes found in completely healthy people.  You should be aware that because our pictures are 
taken for a specific purpose, not all abnormalities that might be detected by other MR scans are necessarily 
seen.  On extremely rare occasions, we might find an abnormality that is significant.  Prior to scanning we will 
ask you to complete a form to indicate what you would like us to do in the event that an abnormality is 
identified.  If we find such an abnormality in your brain, and if you have indicated in advance that you wish to 
know, Prof Stuart Mazzone will call you at the contact number you supply and discuss the findings with you.  
Usually, such contact will be made within 2 weeks of your scan. Although a significant abnormality is extremely 
unlikely, you should be aware that if such an abnormality is detected and you are informed, then this knowledge 
might have consequences for you. Please take the time to consider carefully what it would mean to you if we 
told you of an abnormality in your brain which might, or might not, affect you later in life. Knowledge of an 
abnormality may affect your ability to work in certain professions, obtain life or health insurance and other 
facets of daily living.   
 
Payment  
We will offer you payment of $50 in the form of gift vouchers to reimburse you for your time involved in the 
study.  You will receive this at the conclusion of the second session. 
 
Confidentiality 
Any information obtained in connection with this research that can identify you will remain confidential. It will 
only be disclosed with your permission, except as required by law.  We plan to publish the results of this 
research in peer reviewed scientific journals and at specialised research conferences. In any publication, 
information will be provided in such a way that you cannot be identified. Information collected from individuals 
will be combined into group data for our analyses and reporting so your personal data will not be reported. 
 

 
 
 
 
Page 4 of 4 
Storage of data 
All data for this research will be stored in locked filing cabinets and/or secure electronic databases that can only 
be accessed by the researchers involved in the study or administrators of the electronic resources. These 
records will be maintained for seven years after the publication of study results, to allow sufficient time to 
resolve scientific queries and challenges. 
 
Use of data for other purposes  
It is possible that data collected for the purposes of this study may provide useful information for future 
research projects related to cough and brain structure and function. You can decide whether to approve your 
data being included in future research related to this project. Your approval will be considered in future 
applications to the relevant Human Research and Ethics Committee to undertake future research. If you agree 
to your data being used to answer related research questions in the future, all identifying information will be 
removed to protect your privacy.  
 
Results 
A report summarising the outcomes of this research will be made available to participants after the conclusion 
of the project.  Only de-identified information will be included in the report. 

 
 
 
 
Page 5 of 4 
Complaints 
Should you have any concerns or complaints about the conduct of the project, you are welcome to contact the 
Manager, University of Melbourne Office of Research Ethics and Integrity: 
Manager 
University of Melbourne Office of Research Ethics and Integrity (OREI)  
Research Ethics & Integrity 
Level 4, 161 Barry Street 
The University of Melbourne 
VIC 3010 
 
Tel: +61 3 8344 2073   Email: HumanEthics-Enquiries@unimelb.edu.au         
 
 
Thank you, 
 
 
 
Prof Stuart Mazzone  

 
 
 
CONSENT FORM 
 
 
Project Title:  
 
Behavioural and brain haemodynamic responses to inhalation of capsaicin and adenosine tri
-
phosphate (ATP) in patients with idiopathic chronic cough.
 
 
 
Chief Investigator: Prof Stuart Mazzone 
Department of Anatomy and Neuroscience 
Phone:  8344 6457 
email:   stuart.mazzone@unimelb.edu.au 
Human Ethical Approval number: 1852642 
 
 
I have been asked to take part in the University of Melbourne research project specified above. I have read 
and understood the Explanatory Statement and I hereby consent to participate in this project. 
 
 
 
 
 
 
 
Name of Participant 
 
 
 
 
 
 
Participant Signature 
Date 
 
 
 
I consent to the following: 
Yes 
No 
Completing questionnaires about my daily experiences with coughing 
 
 
 
Providing ratings of sensations associated with inhalation of vapour containing 
chemicals that cause throat irritation 
 
 
Collection of images of my brain that can be used to show regions that respond to 
throat irritation 
 
 
The data that I provide during this study may be used for future research projects